2326 related articles for article (PubMed ID: 7573244)
21. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
22. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
Greene KE; Kettel LM; Yen SS
Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
[TBL] [Abstract][Full Text] [Related]
23. Mode of action of RU 486.
Bygdeman M; Swahn ML; Gemzell-Danielsson K; Svalander P
Ann Med; 1993 Feb; 25(1):61-4. PubMed ID: 8435191
[TBL] [Abstract][Full Text] [Related]
24. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
Croxatto HB; Salvatierra AM; Croxatto HD; Spitz IM
Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
[TBL] [Abstract][Full Text] [Related]
25. Gonadal and pituitary responses to progesterone antagonist ZK 98.299 during the follicular phase of the menstrual cycle in bonnet monkeys.
Puri CP; Patil RK; Elger WA; Vadigoppula AD; Jagan MR
Contraception; 1989 Feb; 39(2):227-43. PubMed ID: 2706991
[TBL] [Abstract][Full Text] [Related]
26. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
27. Expression profiles of endometrial leukemia inhibitory factor, transforming growth factor beta2 (TGFbeta2), and TGFbeta2 receptor in infertile bonnet monkeys.
Sachdeva G; Patil V; Katkam RR; Manjramkar DD; Kholkute SD; Puri CP
Biol Reprod; 2001 Jul; 65(1):1-8. PubMed ID: 11420216
[TBL] [Abstract][Full Text] [Related]
28. Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK 137 316: establishment of a regimen that permits normal menstrual cyclicity.
Zelinski-Wooten MB; Slayden OD; Chwalisz K; Hess DL; Brenner RM; Stouffer RL
Hum Reprod; 1998 Feb; 13(2):259-67. PubMed ID: 9557820
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of ovulation by low-dose mifepristone (RU 486).
Ledger WL; Sweeting VM; Hillier H; Baird DT
Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
[TBL] [Abstract][Full Text] [Related]
30. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
[TBL] [Abstract][Full Text] [Related]
31. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium.
Swahn ML; Bygdeman M; Cekan S; Xing S; Masironi B; Johannisson E
Hum Reprod; 1990 May; 5(4):402-8. PubMed ID: 2113927
[TBL] [Abstract][Full Text] [Related]
32. Effect of low daily doses of mifepristone on ovarian function and endometrial development.
Danielsson KG; Swahn ML; Westlund P; Johannisson E; Seppälä M; Bygdeman M
Hum Reprod; 1997 Jan; 12(1):124-31. PubMed ID: 9043916
[TBL] [Abstract][Full Text] [Related]
33. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
Niaraki MA; Moghissi KS; Borin K
Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
[TBL] [Abstract][Full Text] [Related]
34. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle.
Croxatto HB; Salvatierra AM; Croxatto HD; Fuentealba B
Hum Reprod; 1993 Feb; 8(2):201-7. PubMed ID: 8473419
[TBL] [Abstract][Full Text] [Related]
35. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
36. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
Bergquist C; Nillius SJ; Wide L; Lindgren A
Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
[TBL] [Abstract][Full Text] [Related]
37. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct.
Slayden OD; Zelinski-Wooten MB; Chwalisz K; Stouffer RL; Brenner RM
Hum Reprod; 1998 Feb; 13(2):269-77. PubMed ID: 9557821
[TBL] [Abstract][Full Text] [Related]
38. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
Cameron ST; Thong KJ; Baird DT
Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
[TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat.
Dao B; Vanage G; Li XJ; Bardin CW; Koide SS
Contraception; 1997 Jan; 55(1):35-40. PubMed ID: 9013059
[TBL] [Abstract][Full Text] [Related]
40. The use of anti-progesterones as a medical IUD.
Nieman LK; Loriaux DL
Baillieres Clin Obstet Gynaecol; 1988 Sep; 2(3):609-16. PubMed ID: 3233821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
